<DOC>
	<DOCNO>NCT00266253</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability , pharmacokinetics GK Activator ( 2 ) combination metformin , compare placebo ( metformin monotherapy ) , patient type 2 diabetes mellitus . Patients continue stable dose metformin randomize receive either GK Activator ( 2 ) placebo . The anticipated time study treatment le 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study GK Activator ( 2 ) Patients With Type 2 Diabetes Mellitus Treated With Stable Dose Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>adult patient 3075 year age ; type 2 diabetes mellitus ; individual maximal tolerate daily dose metformin monotherapy &gt; =3 month prior screen . type 1 diabetes mellitus ; oral antihyperglycemic medication , metformin monotherapy , last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>